Introduction
Individualised approaches to drug monitoring can en hance antimicrobial dosing and the treatment of infect ion. Individualised dosing improves clinical outcomes, while minimising the adverse consequences of anti micro bial therapy, especially development of toxicity and antimicro bial resistance (AMR). 1 AMR poses a global threat to human health. 2, 3 A major modifiable driver of AMR is suboptimal dosing of antibiotics. 2 The well reported observation of wide variations in individual pharmacokinetic (PK)-pharmaco dynamic target attain ment has highlighted the need for enhanced methods of drug monitoring to facilitate individualised dose optimisation. 4, 5 Therapeutic drug monitoring is a cornerstone of indi vidual dose optimisation. However, commercial assays are only available for a handful of antibiotics, target ing drugs with a narrow therapeutic index, such as vancomycin-a glycopeptide antibiotic-and the amino glycosides. Therapeutic drug monitoring for these drugs is crucial for preventing toxicity. The use of thera peutic drug monitoring for individualised dosing of anti biotics, such as the βlactams, can improve clinical outcomes. 1, 6 Current methods of therapeutic drug mon itoring for individualised antibiotic dosing present operational and technical barriers. 5, 7 To address these issues, the develop ment of wearable, realtime biosensor technology that can be deployed in a minimally invasive fashion and deliver continuous drug monitoring has been proposed. 4 Microneedle technology has been under development for the past 20 years. 8 To date, the majority of applications for microneedles involve drug and vaccine delivery. 8 However, hollow microneedle arrays have been designed to perform microsampling of extracellular fluid (ECF) to facilitate analysis ex vivo. 9, 10 This approach has similar analytical problems (eg, the need to extract ECF and exvivo analysis) as alternative approaches, such as micro dialysis and therefore cannot be used to facilitate realtime drug monitoring. In contrast, solid microneedle arrays have been used for continuous monitoring of glucose and lactate directly in dermal ECF. [11] [12] [13] [14] Therefore, it might also be possible to use this type of technology to monitor ECF antibiotic concentrations in humans. 4, 15 This study is a first inhuman exploration of a βlactam microneedle array biosensor for the monitoring of phenoxymethylpenicillin, a commonly used antibiotic, in healthy volunteers. 15 It aimed to show the reliability and potential of a minimally invasive microneedle array bio sensor for continuous drug monitoring. The secondary objectives of the study were to explore the accuracy of the microneedle sensors against current gold standards of drug monitoring (ie, blood sampling via cannula and ECF concentrations using microdialysis). Tolerability of wearing the microneedle array was compared with cannula and microdialysis catheter insertion using visual analogue scales.
Methods

Study design
This study was a firstinhuman, proofofconcept study to evaluate the ability of microneedle biosensors to do real time drug monitoring in healthy volunteers. The study was done at the National Institute of Health Research/Wellcome Trust Imperial Clinical Research Facility (Imperial College London, London, UK).
The study protocol was reviewed and approved by LondonHarrow Regional Ethics Committee.
Participants
Between April and August, 2018, participants were identified through emails sent to a healthy volunteer database containing over 2000 potential volunteers, held at Imperial College Clinical Research Facility. Male and female healthy volunteers older than 18 years were elig ible for inclusion. Volunteers were excluded if they had evidence of active infection, allergies to phenoxymethyl penicillin, were at high risk of skin infection (eg, atopic dermatitis) near the sensor site, or presented with anaemia (defined as haemoglobin <13 g/dL for men and <12 g/dL for women) during screening. If volunteers responded to the advertisement, they were initially screened via email followed by a screening visit at the Clinical Research Facility. Those meeting study criteria at screening were invited to participate in the study. All participants provided written, informed consent.
Research in context
Evidence before the study We searched PubMed, Web of Science, and Google Scholar, from inception to May 24, 2019, for studies reporting methods for real-time antibiotic drug monitoring, using main search terms "drug monitoring", "antibiotic", "real-time", and "continuous". We only considered original research and review articles published in English. Although several biosensor and microneedle technologies have been reported in the literature, no in-human studies have been done to our knowledge. Invasive techniques, using biosensors mounted on central venous catheters inserted into ambulatory rodents have previously been described. Hollow microneedle technologies have been reported and tested in vitro; however, these technologies do not provide true in-vivo monitoring potential because of the requirement for extracellular fluid extraction via microsampling. Solid microneedle arrays have been used to show real-time glucose monitoring in healthy volunteers and patients with diabetes in proof-of-concept studies, suggesting that solid microneedle array antibiotic biosensors could potentially provide real-time, in-vivo antibiotic drug monitoring.
Added value of the study
This first-in-human study provides proof-of-concept that a minimally invasive, microneedle β-lactamase biosensors can be used for real-time, in-vivo antibiotic drug monitoring. This study provides evidence to support the wider exploration of microneedle antibiotic monitoring in patients and for a broader range of antimicrobial drugs. It is also the first step towards automated, individualised antibiotic dosing in humans through the application of closed-loop control systems.
Implications of all the available evidence
As well as supporting future exploration of real-time antibiotic monitoring, this study adds to the growing body of literature showing proof-of-concept for direct in-vivo monitoring of drugs using solid microneedle array biosensors. The implications of this research extend beyond antibiotics and even drugs, also providing evidence for biomarker monitoring in vivo using solid microneedle arrays.
Procedures
Healthy volunteers were recruited to wear a microneedle βlactam biosensor for up to 6 h while being dosed at steady state with oral phenoxymethylpenicillin. Oral phenoxy methylpenicillin was the βlactam chosen because of its convenience (ie, it can be delivered orally rather than by injection), well documented safety profile, and narrow spectrum of activity. Participants took five doses of phenoxymethyl penicillin (500 mg every 6 h, a standard treatment dose for bacterial infections in adults) on an empty stomach before attending the study, documenting doses on a selfreported diary card.
On arrival at the study centre, two microneedle sensors were applied to the participant's forearm. A cannula for blood sampling was inserted in a large vein in the antecubital fossa. A microdialysis catheter was inserted subcutaneously in the forearm close to the microneedle array. Participant baseline characteristics (height, weight, gender, age, and bodymass index [BMI]) were collected and glomerular filtration rate estimated using the CockcroftGault equation. Participants were dosed on an empty stomach with 500 mg oral phenoxymethylpenicillin (ie, at time=0 min). The output from the microneedle array sensors was recorded for comparison to concomitant blood and tissue ECF PK samples. The blood and ECF samples were taken via a cannula and by microdialysis, respectively.
Microneedle biosensors
The development and invitro validation of the microneedle array biosensors used in this study have been described in detail. 15, 16 Figure 1 summarises the microneedle array structure and application process. The polycarbonate microneedle array structure is metallised to produce four independent electrodes. Each electrode is created by first metallising the electrode areas with an adhesion layer of chromium (110 nm). Three of the electrodes are then coated with gold (150 nm) to create independent working electrodes. The fourth electrode is metallised with 150 nm of silver and then chloridised to act as a silver-silver chloride reference electrode. The working electrodes are subsequently modified by electrodeposition of iridium oxide to measure changes in pH. 15, 16 Finally, a hydrogel layer containing an extended spectrum βlactamase from Enterobacter cloacae (Sekisui Diagnostics, Tokyo, Japan) is added. 15, 16 Sterilisation is achieved with Colbalt60 gamma radiation.
The sensors are applied to the forearm with firm pressure for 60 s and secured in place with a transparent medical dressing. The sensors are connected to a potentiostat and the open circuit potential of the working electrode versus the reference electrode recorded. As phenoxymethylpenicillin in the ECF diffuses into the hydrogel layer, it is hydrolysed to penicilloate and a proton by βlactamase. Therefore, as the concentration of phenoxymethylpenicillin in the tissue increases, the concentration of protons generated at the sensor surface increases. This process leads to a fall in the local pH at the sensor surface, which is detected as an increase in open circuit potential as the equilibrium of iridium oxide oxidation states (ie, the ratio of iridium + 3 to iridium + 4) within the sensor is shifted. For calibration of the work ing electrodes, a control electrode is also worn. The control electrode is identical to the working electrode but without βlactamase enzyme in the hydrogel layer. Its use provides a background potential that is subtracted from the working electrode potential to compensate for any During the study period, each participant wore two microneedle devices. One containing working elec trodes and one containing the control electrode. The open cir cuit potential (in mV) was recorded 200 times every second for each electrode. This measurement provided data for three phenoxymethylpenicillin sensors and one control array per participant. The electrochemical signal was recorded with an inhouse instrument for potentio metric recording of biosignals (Imperial College London, London, UK). 17
Blood samples
A maximum of 15 blood samples were acquired before and after the final (sixth dose, time=0 min) dose of phenoxymethylpenicillin. Blood samples were taken via a cannula at times -30, 0, 10, 20, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 min. Samples were allowed to clot for 10 min and then placed on ice. They were centrifuged (at 3000 G for 10 min) within 30 min. The serum was stored at -80°C until analysed. Analysis was done using highperformance liquid chromatography tandem mass spectrometry at Bristol Antimicrobial Reference Laboratory (Bristol, UK). Both total and free (unbound) drug concentrations were determined. Free antibiotic concentration was determined for individuals by perform ing ultrafiltration (Centrifree ultrafiltration, 30 kDa molec ular weight cutoff; SigmaAldrich, Schnelldorf, Germany). Each participant had free drug concentration determined at three collection timepoints and an average was calcu lated. The limit of quantification for the highperformance liquid chromatography tandem mass spectrometry assay was 0·10 mg/L.
Microdialysis
ECF phenoxymethylpenicillin concentrations were deter mined through continuous microdialysis. A microdialysis catheter (CMA 63 microdialysis catheter, 20 kDa molecular weight cutoff; Linton Instruments, Norfolk, UK) was inserted into the subcutaneous tissue of the forearm after application of topical local anaesthetic. The catheter was perfused using sterile T1 perfusion fluid (sodium 147 mmol/L, potassium 4 mmol/L, calcium 2·3 mmol/L, chloride 156 mmol/L; Linton Instruments, Norfolk, UK) with a flucloxacillin internal standard (10 mg/L). [18] [19] [20] The rate of perfusion was 2 µL/min with microvials changed every 15 min during the study period. The first 30 min was designated the equilibrium period with samples obtained during this period excluded from the analy sis. Microdialysis sampling commenced 1 h before phenoxymethylpenicillin administration (ie, time=0 min) and continued until the end of each study period (240 min). Microdialysis vials were stored at -80°C follow ing collection until analysed. Analysis was done using highperformance liquid chromatography tandem mass spectrometry at Bristol Antimicrobial Research Centre (Bristol, UK). The limit of quantification for the phen oxymethylpenicillin and flucloxacillin assays were both 0·10 mg/L.
Invivo recovery of phenoxymethylpenicillin in the micro dialysate solution was determined from the meas ured loss of the flucloxacillin internal standard across the microdialysis membrane for individual participants:
where C in is the concentration of flucloxacillin meas ured in the perfusate and C out is the concentration of flucloxacillin measured in the microdialysate for each indi vidual volunteer. This invivo recovery was used to estim ate actual tissue ECF concentration from the dialysate concentration.
Outcomes
The primary outcome of this study was to determine whether a microneedle biosensor could be used to mon itor phenoxymethylpenicillin concentrations in human dermal ECF.
Data processing and analysis
Microneedle data, in mV, were recorded in realtime. All processing and calibration into phenoxymethylpenicillin concentration was done after data collection. Signal pro cessing was done by firstly subtracting the control sensor from individual working electrodes to correct back ground drift. Noise was corrected for using first order locally estimated scatterplot smoothing (LOESS) filters in IgorPro8 (WaveMetrics, Lake Oswego, OR, USA).
Given the study aims, the small number of sensors, and potential persontoperson and sensortosensor variation, separate calibration and validation cohorts would be challenging. We chose to split individual sensor data into independent calibration and validation sets. To calibrate individual sensors, a random selection of time points were plotted against corresponding microdialysis data. For each individual sensor, a first order polynomial was determined by linear regression between sensor output and microdialysis tissue concentration. This polynomial was then used to convert sensor output (mV) to phenox ymethylpenicillin concentration (mg/L) in the validation dataset. Concentration data from all micro needle sensor validation sets were then compared with microdialysis results at corresponding timepoints using BlandAltman plots to examine for bias and limits of agreement.
As calibration of the microneedles was based on regress ion of microdialysis results, the method of concentration determination for the microneedle arrays is not entirely independent of the microdialysis data. However, the purpose of Bland-Altman plot in this study was to show the methods are in agreement over the entire dataset using independent measurements of calibration and validation. Therefore, while considering this limitation, we agreed that this method of evaluation remained valid Percentage of penicillin recovery=100 × (C in -mean C out /C in ) See Online for appendix for initial comparison of the microneedles against the current gold standard, microdialysis.
Limits of detection of the microneedle biosensors were estimated as:
where Csd is the standard deviation of the yintercept (C) of a first order polynomial generated by fitting a line of regression through the pooled microneedle array data and M represents the slope function for the same polynomial. 21 Limit of quantification was estimated as: 21 The PK profiles of free serum, microdialysis, and micro needle data were determined and compared using noncompartmental analysis. This analysis was done with Pmetrics software, in R (R Core Development Team). 22 Figures were plotted using IgorPro8 to estimate the area under the concentration-time curve (AUC), maximum concentration (Cmax), and time to maximum concentra tion for each measurement method. Statistical analysis was done using t tests in R.
Visual analogue scoring
During the study visit, participants completed visual analogue scoring from 0 to 10 cm, rating pain or discomfort caused by cannula, microdialysis catheter, and the micro needles. Visual analogue scoring was collected immediately and 3 h after insertion. Mean scores were visually com pared. Statistical analysis was not done as it was not powered to account for type 2 errors.
The study was registered with ClinicalTrials.gov in February, 2019, number NCT03847610. Registration was delayed because of an administrative error during local registration that should have facilitated ISRCTN registra tion. The registered study protocol was not amended in anyway following ethics committee approval. The protocol is available in the appendix.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the Results 150 responses to the initial advertisement were received. Of these, 81 (54%) completed the email screening. Screen ing visits at the Clinical Research Facility were organised with 25 (31%) of 81 individuals. 17 (68%) were eligible for inclusion. Three (18%) of 17 withdrew after screening, and three were held on standby for the study. We had standby participants because we only needed to recruit ten participants in total and recruitment screening visits were staggered. In total, 11 (65%) volunteers participated in the study. One volunteer withdrew consent to undergo microdialysis on the study day and was withdrawn from the analysis. The participant did not cite a reason for declining microdialysis catheter insertion. Therefore, ten volunteers were included in the study. The mean age of participants was 42 years (SD 14) and seven (70%) of ten participants were men. Participants mean height was 174 cm (11), weight 74 kg (15) , and BMI 24 kg/m² (3) . Mean creatinine clearance was 114 mL/min (29) .
Each participant wore a microneedle array containing three enzymecoated sensors (30 sensors in total) and one array containing the control sensor (ten sensors in total). Data for 25 (83%) of 30 enzymecoated sensors were available for analysis. In two cases (participant 1 and 5), one of the three working electrodes failed due to poor electrical connectivity. For participant 9, data from all three working electrodes became corrupted, meaning that data for this individual were not available for analysis.
Microneedle data were recorded for a mean of 3·74 h (SD 0·48). A mean of 13 blood samples (SD 1) and 14 microdialysis PK samples (3) were taken per participant. Figure 2A shows raw microneedle data for the three microneedle arrays (mV) plotted against free serum and ECF phenoxymethylpenicillin concentration (mg/L). Figure 2B shows LOESS smoothing of the microneedle data and figure 2C shows final calib rated microneedle data (mg/L) against free serum and ECF (microdialy sis) determined phenoxymethyl penicillin concentrations. Overall, there was a good agreement with a mean difference between microneedle and microdialysis meas urements of -0·16 mg/L and the majority of points were within the 1·96 SD range (0·82 to -1·30; figure 3) . Deviation beyond the 1·96 SD range can be attributed to a single individual's microneedle array. Limit of detection was estimated at 0·17 mg/L and limit of quantification at 0·55 mg/L. Median coefficient of variation (CV) between sensors for the same individual was 7% (IQR 4-17).
PK parameters for free serum phenoxymethylpenicillin concentration were compared with parameters deter mined using the microneedle biosensors. Phenoxy methylpenicillin protein binding was variable between individuals with a mean free phenoxymethylpenicillin fraction of 23% (SD 4; table 1; CV 18%). Free serum and microneedle PK had similar mean AUCs (1·77 mg × h/L [SD 0·59] for free serum vs 1·67 mg × h/L [1·00] for microneedle; 95% CI -0·77 to 0·97; p=0·81; tables 1, 2). Free serum Cmax was significantly higher than micro needle measurements of the ECF (1·32 mg/L [0·60] vs 0·64 mg/L [0·30]; 0·21 to 1·17; p=0·0095; tables 1, 2).
All modalities of phenoxymethylpenicillin measure ment were well tolerated. Mean visual analogue scoring for microneedles, microdialysis catheter, and cannula was low. At insertion, microneedle pain or discomfort scored a mean of 0·9 cm (SD 1·5) falling to 0·1 cm (0·2) at 3 h. Cannula insertion scored 0·2 cm (0·2) on insertion rising to 0·5 cm (0·8) at 3 h. Microdialysis scored 1·5 cm (3) at insertion and 0 (0) at 3 h. No participants experienced any adverse events (data not shown).
Discussion
In this firstinhuman evaluation of microneedle antibiotic drug monitoring, we showed that a microneedle βlactam biosensor could monitor changes in ECF drug, could be calibrated to drug concentration, and was well tolerated by healthy volunteers. PK profiles of ECF phenoxymethyl penicillin were similar between micro dialysis and micro needle methods but showed highly variable PK between participants. AUCs of free antibiotic in serum and ECF were similar, but highly variable between participants. These results are in line with documented variability in the PK of phenoxymethylpenicillin. 23 Realtime, minimally invasive, microneedle drug monitor ing provides the ability to monitor and poten tially react to changing drug PK within the individual and might support the development of individualised app roaches to antibiotic dosing. Within our study, microneedle bio sensors were calibrated against, and subsequently compared with, individual discrete tissue microdialysis measurements, which is the current gold standard for determining ECF drug concentration. Using this method, the microneedle biosensors had high concordance with microdialysis in terms of phenoxy methylpenicillin PK profile and determining ECF drug concentration, pro viding a proofofconcept for their application in wider clinical practice. Table 3 compares potential benefits of microneedle versus microdialysis methods for ECF drug monitoring. 15, 18, [24] [25] [26] Similarly, the potential benefit of micro needle technology over blood sampling is that no laboratory analytics are required, monitoring can be continuous, and the process is minimally invasive with no exposure to blood of other potential hazardous bodily fluids. 9, 10 Microneedle ECF antibiotic measurement might facilitate optimisation of other compartment drug con centrations in the future, including serum. Free (un bound) concentration of drug is the current gold standard, given that free drug is in equilibrium between body compartments, such as blood and ECF. 27 Therefore, the development of minimally invasive microneedle sensors might provide a mechanism to guide blood compartment dose optimisation. 4 This study supports this argument by showing similar AUCs in serum and ECF. Through the greater exploration of this technique and linkage to other drug compartments, dose optimisation might become a reality. Several outstanding variables must now be explored, including the effect of conditions such as sepsis on ECF volume expansion and pH change, and the abil ity of microneedles to detect both subtherapeutic and supratherapeutic drug concentrations accurately. Based on preliminary invitro analysis and data from this study, we anticipate that the microneedle biosensors should perform within appropriate limits of detection. 15, 16 Further more, the use of a control sensor allows for changes in individual ECF pH to be controlled for in the calibration step. 15, 16 Finally, microdialysis studies already provide data showing PK variability within ECF in critical illness. Given the variable PK of phenoxymethylpenicillin in ECF, this study provides initial evidence to support the appropriateness of microneedles to cope with wide ECF variations in sepsis.
The current study aimed to show the potential of microneedle sensors through calibration against indi vidual microdialysis data. However, for wider roll out and evaluation when microdialysis is not available, alternative standardised calibration techniques are required. This process might be achieved through concurrent free drug analysis of serum allowing estimation and comparison of AUCs between com partments, or through standardised calibration of devices based on pooled data. Furthermore, the enzymebased biosensor used in this study might not be appropriate for all antibiotics, such as aminoglyco sides, or in the presence of enzyme inhibitors, such as amoxicillin-clavulanic acid or piperacillin-tazobactam drug combinations. 4 The selection and functionalisation of aptamer technology has already been shown to be possible for realtime drug monitoring and offers an alternative sensing modality for application to microneedles. 28, 29 Fin ally, the combination of microneedle sensing with methods of individualised antibiotic dosing, such as closedloop control systems, is yet to be shown in vivo. 4, 30 The current study also has several limitations. This study was done in healthy volunteers using an orally administered phenoxymethylpenicillin designed to show proof of concept for realtime, minimally invasive mon itoring of antibiotics in humans. Drug PK, especially in ECF, was highly variable between individuals making grouped sensor analysis challenging. Data from five (16%) of 30 microneedle electrodes were not available for analysis. Furthermore, the study of healthy volunteers makes generalisability to patients challenging, particularly in reference to changes that occur in sepsis and with polypharmacy. This study does, however, provide proof ofconcept for microneedlebased antibiotic therapeutic drug monitoring and will be further explored in patient populations now that the safety and potential reliability of such technology has been shown in vivo.
In conclusion, this firstinhuman study of microneedle array biosensors for antibiotic therapeutic drug monitoring has shown that minimally invasive, microneedle sensors are able to continuously monitor ECF antibiotic concen trations in line with current microdialysis gold standards. The microneedle results showed similar free drug AUC when compared with serum AUC. The PK profiles were also similar between microneedle and microdialysis methods of ECF monitoring, with highly variable PK. Further work will explore the role of these sensors in obtaining necessary data to optimise βlactam dosing in patient populations and as part of realtime dose optimisation using closedloop control systems.
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Potential for disruption of local tissues, inflammation, and bleeding during insertion 18 Practicality for use in clinical practice Easy application, no needles or skin puncture required Requires training and puncture of the skin
In-vivo measurement
Direct detection in vivo Not applicable (diasylate collected and analysed ex vivo)
Quantification
Direct quantification of drug concentration 15, [24] [25] [26] Estimation of drug concentration calculated often using an internal standard method [18] [19] [20] Resolution 
